Get the Stockscreener App
9.89
1.69%
-0.17
After Hours:
10.55
0.66
+6.67%
Ocular Therapeutix Inc Stock (OCUL) Latest News
Braidwell LP Has $19.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Knoll Capital Management LLC Purchases 400,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 29, 2024) - GuruFocus.com
Neuropathic Ocular Pain Market Is Booming Worldwide 2024-2031 | - openPR
Acuta Capital Partners LLC Cuts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 28, 2024) - GuruFocus.com
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
Ocular Therapeutix chief scientific officer sells shares worth $26,561 By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief scientific officer sells shares worth $26,561 - Investing.com India
Ocular Therapeutix chief development officer sells shares worth $26,101 By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief development officer sells shares worth $26,101 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 - Investing.com
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock By Investing.com - Investing.com Australia
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock - Investing.com
Ocular Therapeutix executive sells shares for $16,326 By Investing.com - Investing.com UK
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewswire
OCUL (Ocular Therapeutix) EBITDA per Share : $-1.15 (TTM As of Sep. 2024) - GuruFocus.com
Banco Santander S.A. Sells 205,137 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - MSN
Ocular Therapeutix Q3 2024 Earnings Preview - MSN
(OCUL) Technical Data - Stock Traders Daily
Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Ocular Therapeutix Posts Mixed Third Quarter 2024 Results - Vision Monday
Ocular Therapeutix: Q3 Earnings Snapshot - Houston Chronicle
Ocular Therapeutix Reports Q3 2024 Financial Results - TipRanks
Ocular Therapeutix Inc. (OCUL) Quarterly 10-Q Report - Quartzy
Avoro Capital Advisors LLC Acquires Significant Stake in Ocular Therapeutix Inc - GuruFocus.com
Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ocular Therapeutix Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com
Ocular Therapeutix Inc Reports Q3 2024 Earnings: Revenue at $15. - GuruFocus.com
Q3 2024 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus.com
Ocular Therapeutix appoints Namrata Saroj as CBO - The Pharma Letter
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights - The Manila Times
Ocular Therapeutix Inc. Appoints Namrata Saroj, OD, as Chief Business Officer - Vision Monday
A Peek at Ocular Therapeutix's Future Earnings - Benzinga
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV - The Manila Times
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnin - GuruFocus.com
Ocular Therapeutix™ to Present at the Jefferies London - GlobeNewswire
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings - Yahoo Finance
Ocular Therapeutix appoints new Chief Business Officer By Investing.com - Investing.com Canada
Ocular Therapeutix appoints new Chief Business Officer - Investing.com
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer - The Manila Times
Ocular Therapeutix (OCUL) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024 - GlobeNewswire
Rosalind Advisors Inc. Grows Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Vanguard Group Inc's Strategic Reduction in Ocular Therapeutix I - GuruFocus.com
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):